All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Pasritamig Displays Safety, Durable Disease Control in Heavily Pretreated mCRPC

July 14th 2025

Pasritamig was safe and produced durable responses in heavily pretreated metastatic castration-resistant prostate cancer.

Adjuvant Dalpiciclib Plus Endocrine Therapy Improves iDFS in HR+/HER2– Early Breast Cancer

July 14th 2025

Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Imatinib Remains Standard of Care in GIST With ‘a Long Way to Go’

July 13th 2025

Breelyn Wilky, MD, discusses the importance of recognizing GIST Awareness Day and research towards moving the needle in the GIST treatment paradigm.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Cross-Disciplinary Expert Alliances Drive Progress in Malignant PEComa Diagnosis and Management

July 12th 2025

Richard F. Riedel, MD, discusses the rarity of PEComa, challenges with managing this disease, and the role of sarcoma specialists in staging and treatment.

Oncologists Highlight Key Takeaways and Abstracts From the 2025 ESMO GI Cancers Congress

July 11th 2025

Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.

Dostarlimab Plus Chemo Prolongs Time to First, Second Subsequent Therapy Regardless of Age in Endometrial Cancer

July 11th 2025

After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.

Most Patients With Advanced Melanoma Who Received Pre-Surgical Immunotherapy Remain Alive and Disease Free Four Years Later

July 11th 2025

Researchers found potential biomarkers that can highly predict which patients with stage III melanoma have better outcomes or are at high risk of recurrence.

Lisaftoclax Wins Chinese Approval in Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

July 11th 2025

The NMPA has approved lisaftoclax in adult patients with relapsed/refractory CLL/SLL.

FDA Grants Orphan Drug Designation to ADRX-0405 for Gastric Cancer

July 11th 2025

ADRX-0405 has received orphan drug designation from the FDA for the treatment of patients with gastric cancer.

A Closer Look at Issues With the Expanding Role of Precision Medicine in Cancer Management

July 11th 2025

Maurie Markman, MD, raises concerns about public health priorities and resource allocation in light of the expanding role of precision medicine in cancer.

Glofitamab Plus Pirtobrutinib Yields High Activity, Tolerability in Covalent BTK Inhibitor–Exposed MCL

July 11th 2025

Results from the GoldiLox trial showed high complete and MRD-negative responses with glofitamab plus pirtobrutinib in covalent BTK inhibitor–exposed MCL.

FDA Releases CRLs for Previous Drug and Biologic Product Applications

July 10th 2025

The FDA has published a collection of complete response letters that were seeking the approval of drugs or biologic products between 2020 and 2024.

Patritumab Deruxtecan Shows CNS Efficacy in Metastatic Breast Cancer With Brain Metastases

July 10th 2025

Treatment with HER3-DXd led to intracranial responses with a tolerable safety profile in patients with metastatic breast cancer and brain metastases.

BGB-16673 Informs Future Direction for BTK Degraders in Relapsed/Refractory CLL/SLL

July 10th 2025

Lydia Scarfò, MD, details the early efficacy and safety profile of BTK degrader BGB-16673 for the treatment of patients with relapsed/refractory CLL/SLL.

Fox Chase Cancer Center Researcher Helps Finds Key Resistance Mechanism in Breast Cancer That Could Lead to More Effective Treatment

July 10th 2025

New research from Fox Chase Cancer Center uncovers mechanisms of breast cancer resistance to CDK4/6 inhibitors and offers innovative treatment strategies.

Enzalutamide Plus Leuprolide Yields OS Benefit in nmHSPC With Biochemical Recurrence

July 10th 2025

The combination of enzalutamide and leuprolide improved OS vs leuprolide alone in nmHSPC with high-risk biochemical recurrence at high risk for metastasis.

European Commission Approves First-Line Tislelizumab Plus Chemo for Metastatic Nasopharyngeal Carcinoma

July 10th 2025

The European Commission has approved tislelizumab plus gemcitabine/cisplatin for adults with recurrent or metastatic nasopharyngeal carcinoma.

Targeted Therapies Broaden Treatment Options for CDK4/6 Inhibitor–Resistant, HR+ Breast Cancer

July 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses the importance of optimizing endocrine-based therapies in hormone receptor–positive metastatic breast cancer.